hereditary angioedema (HAE)
Rare disease · 2010–2024
4decisions
2medicines
2carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lanadelumab Preventative treatment of hereditary angioedema (HAE) Types 1 or 2 in patients aged 2 to 11 years who have experienced at least one treated acute attack within… | Nov 2024 | Recommended | 2 individuals |
| icatibant Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase inhibitor deficiency. | Jul 2017 | Recommended | no section in document |
| icatibant Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase-inhibitor deficiency. | Nov 2016 | Not recommended | input received |
| icatibant Treatment of laryngeal/oro-pharyngeal and severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase… | Jul 2010 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.